Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Libtayo in high-risk stage III cutaneous squamous cell carcinoma
NCT04632433Phase 2Active, not recruiting
- Start
- Feb 2021
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC). Started Feb 2021; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04632433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632433.